Uveal melanoma carries a risk of metastasis, which may occur before the disease is even detected. Moreover, even when uveal melanoma is treated, there's a good chance that the radiation used during therapy will result in radiation retinopathy. Prithvi Mruthyunjaya, MD, MHS, reviews the state of uveal melanoma therapies in clinical trials and discusses how doctors might employ new tactics to prevent metastatic disease. Also, Amy Schefler, MD, outlines a trial examining how patients with radiation retinopathy respond to anti-VEGF therapy. How could this change the visual function of patients whose cancer treatments left them visually impaired?

This editorially independent podcast is supported with advertising.